ADIPOQ and metabolic dysfunction-associated steatotic liver disease: In a phase 1b/2a trial (A Multiple Ascending Dose Study of BIO89–100 in Subjects With Biopsy Confirmed NASH or NAFLD and at High Risk of NASH, NCT04048135, phase 1b/2a), 12-week treatment with the pegozafermin significantly reduced hepatic volume and fat fraction and improved NAFLD-related markers (TG, LDL-C, HDL-C, non-HDL-C, adiponectin, bodyweight, ALT, and PRO-C3) [135].